


**UMIN-CTR Clinical Trial**
[BACK](#) [TOP](#) [UMIN-CTR English Home](#) [Glossary \(Simple\)](#) [FAQ](#) [Search clinical trials](#)
**Name:** **UMIN ID:**

**Recruitment status** Enrolling by invitation  
**Unique ID issued by UMIN** UMIN000030539  
**Receipt No.** R000034862  
**Official scientific title of the study** Clinical usefulness of second generation colon capsule endoscopy (CCE-2) in patients with ulcerative colitis  
**Date of disclosure of the study information** 2017/12/24  
**Last modified on** 2017/12/24

\* This page includes information on clinical trials registered in UMIN clinical trial registered system.

\* We don't aim to advertise certain products or treatments

Basic information	
<b>Official scientific title of the study</b>	Clinical usefulness of second generation colon capsule endoscopy (CCE-2) in patients with ulcerative colitis
<b>Title of the study (Brief title)</b>	Clinical usefulness of colon capsule endoscopy in patients with ulcerative colitis
<b>Region</b>	Japan

Condition	
<b>Condition</b>	Patient with ulcerative colitis
<b>Classification by specialty</b>	Gastroenterology
<b>Classification by malignancy</b>	Others
<b>Genomic information</b>	NO

Objectives	
<b>Narrative objectives1</b>	To clarify the clinical usefulness, safety, and compliance of second generation colon capsule endoscopy (CCE-2) in patients with ulcerative colitis. To examine whether the severity of mucosal inflammation by CCE-2 is associated with thereafter bad outcome such as clinical relapse.
<b>Basic objectives2</b>	Safety,Efficacy
<b>Basic objectives -Others</b>	
<b>Trial characteristics_1</b>	
<b>Trial characteristics_2</b>	Pragmatic
<b>Developmental phase</b>	Not applicable

Assessment	
<b>Primary outcomes</b>	1. The rate of total colon observation within its battery life, and transit time 2. Severity of mucosal inflammation in clinical remission assessed by CCE using Mayo endoscopic subscore (Mayo ES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

<b>Key secondary outcomes</b>	<ol style="list-style-type: none"> <li>1. Cleansing level with a 4-point grading scale (poor, fair, good, and excellent)</li> <li>2. Adverse events</li> <li>3. Relapse-free survival, Exacerbation-free survival, surgery-free survival</li> <li>4. Acceptability of CCE assessed by questionnaire survey.</li> </ol>
-------------------------------	--

<b>Base</b>	
<b>Study type</b>	Observational

<b>Study design</b>	
<b>Basic design</b>	
<b>Randomization</b>	
<b>Randomization unit</b>	
<b>Blinding</b>	
<b>Control</b>	
<b>Stratification</b>	
<b>Dynamic allocation</b>	
<b>Institution consideration</b>	
<b>Blocking</b>	
<b>Concealment</b>	

<b>Intervention</b>	
<b>No. of arms</b>	
<b>Purpose of intervention</b>	
<b>Type of intervention</b>	
<b>Interventions/Control_1_1</b>	
<b>Interventions/Control_1_2</b>	
<b>Interventions/Control_1_3</b>	
<b>Interventions/Control_1_4</b>	
<b>Interventions/Control_1_5</b>	
<b>Interventions/Control_1_6</b>	
<b>Interventions/Control_1_7</b>	
<b>Interventions/Control_1_8</b>	
<b>Interventions/Control_1_9</b>	
<b>Interventions/Control_1_10</b>	

<b>Eligibility</b>	

<b>Age-lower limit</b>	16 years-old <=
<b>Age-upper limit</b>	80 years-old >
<b>Gender</b>	Male and Female
<b>Key inclusion criteria</b>	1. Patients with known ulcerative colitis Category A: outpatient, in clinical remission defined as the Rachmilewitz index of 0-4 points Category B: active inpatient 2. Written informed consent
<b>Key exclusion criteria</b>	1. Patients with dysphagia 2. Pregnant or possible pregnant women 3. Patients with a pacemaker or other implanted electromedical device 4. Patients with present or past history of small and large bowel obstruction 5. Patients with a contraindication to bowel preparation (congestive heart failure, renal insufficiency, a life-threatening condition) 6. Patients with an allergy to polyethylene glycol, magnesium citrate, sennoside, metoclopramide or mosapride citrate 7. Patients who will undergo MRI 2 weeks after CCE 8. Patients inappropriate for this study by other reasons judged by investigators
<b>Target sample size</b>	50

#### Research contact person

<b>Name of lead principal investigator</b>	Satoshi Osawa
<b>Organization</b>	Hamamatsu University School of Medicine
<b>Division name</b>	Department of Endoscopic and Photodynamic Medicine
<b>Address</b>	1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
<b>TEL</b>	+81-53-435-2261
<b>Email</b>	sososawa@hama-med.ac.jp

#### Public contact

<b>Name of contact person</b>	Satoshi Osawa
<b>Organization</b>	Hamamatsu University School of Medicine
<b>Division name</b>	Department of Endoscopic and Photodynamic Medicine
<b>Address</b>	1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
<b>TEL</b>	+81-53-435-2261
<b>Homepage URL</b>	
<b>Email</b>	sososawa@hama-med.ac.jp

#### Sponsor

<b>Institute</b>	Hamamatsu University School of Medicine
<b>Institute</b>	
<b>Department</b>	

#### Funding Source

<b>Organization</b>	Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine
<b>Organization</b>	
<b>Division</b>	

<b>Category of Funding Organization</b>	Self funding
<b>Nationality of Funding Organization</b>	

Other related organizations	
<b>Co-sponsor</b>	
<b>Name of secondary funder(s)</b>	

Secondary IDs	
<b>Secondary IDs</b>	NO
<b>Study ID_1</b>	
<b>Org. issuing International ID_1</b>	
<b>Study ID_2</b>	
<b>Org. issuing International ID_2</b>	
<b>IND to MHLW</b>	

Institutions	
<b>Institutions</b>	浜松医科大学医学部附属病院 (静岡県)/Hamamatsu University Hospital

Other administrative information	
<b>Date of disclosure of the study information</b>	2017 Year 12 Month 24 Day

Progress	
<b>Recruitment status</b>	Enrolling by invitation
<b>Date of protocol fixation</b>	2015 Year 10 Month 01 Day
<b>Anticipated trial start date</b>	2015 Year 10 Month 01 Day
<b>Last follow-up date</b>	2018 Year 12 Month 31 Day
<b>Date of closure to data entry</b>	
<b>Date trial data considered complete</b>	
<b>Date analysis concluded</b>	

Related information	
<b>URL releasing protocol</b>	
<b>Publication of results</b>	Unpublished
<b>URL releasing results</b>	

<b>Results</b>	
<b>Other related information</b>	consecutive cases, prospective study Actual study start date: October 2015 now registering

<b>Management information</b>	
<b>Registered date</b>	2017 Year 12 Month 24 Day
<b>Last modified on</b>	2017 Year 12 Month 24 Day

<b>Link to view the page</b>	
<b>URL(English)</b>	<a href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034862">https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034862</a>

<b>Research Plan</b>	
<b>Registered date</b>	<b>File name</b>

<b>Research case data specifications</b>	
<b>Registered date</b>	<b>File name</b>

<b>Research case data</b>	
<b>Registered date</b>	<b>File name</b>

Back

[Contact us.](#)

